

Ewa Eo Oglodek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/203375/publications.pdf>

Version: 2024-02-01

22
papers

427
citations

840776

11
h-index

752698

20
g-index

26
all docs

26
docs citations

26
times ranked

749
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of the neuroendocrine and immune systems in the pathogenesis of depression. <i>Pharmacological Reports</i> , 2014, 66, 776-781.	3.3	64
2	Melatonin and neurotrophins NT-3, BDNF, NGF in patients with varying levels of depression severity. <i>Pharmacological Reports</i> , 2016, 68, 945-951.	3.3	59
3	Comparison of chemokines (CCL-5 and SDF-1), chemokine receptors (CCR-5 and CXCR-4) and IL-6 levels in patients with different severities of depression. <i>Pharmacological Reports</i> , 2014, 66, 920-926.	3.3	51
4	The influence of atypical antipsychotic drugs on sexual function. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1655.	2.2	35
5	The MCP-1, CCL-5 and SDF-1 chemokines as pro-inflammatory markers in generalized anxiety disorder and personality disorders. <i>Pharmacological Reports</i> , 2015, 67, 85-89.	3.3	33
6	The role of PON-1, GR, IL-18, and OxLDL in depression with and without posttraumatic stress disorder. <i>Pharmacological Reports</i> , 2017, 69, 837-845.	3.3	24
7	The impact of antipsychotics as a risk factor for thromboembolism. <i>Pharmacological Reports</i> , 2018, 70, 533-539.	3.3	24
8	Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 $\hat{\pm}$, PMN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Pharmacological Reports</i> , 2018, 70, 110-118.	3.3	23
9	Serum concentrations of chemokines (CCL-5 and CXCL-12), chemokine receptors (CCR-5 and CXCR-4), and IL-6 in patients with posttraumatic stress disorder and avoidant personality disorder. <i>Pharmacological Reports</i> , 2015, 67, 1251-1258.	3.3	22
10	Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. <i>Pharmacological Reports</i> , 2013, 65, 279-287.	3.3	16
11	Assessing the serum concentration levels of NT-4/5, GPX-1, TNF- $\hat{\pm}$, and l-arginine as biomediators of depression severity in first depressive episode patients with and without posttraumatic stress disorder. <i>Pharmacological Reports</i> , 2017, 69, 1049-1058.	3.3	16
12	Sense of alexithymia in patients with anxiety disorders comorbid with recurrent urticaria. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 995.	2.2	11
13	Is Water-Only Fasting Safe?. <i>Global Advances in Health and Medicine</i> , 2021, 10, 216495612110311.	1.6	10
14	Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 972-972.	2.3	7
15	A study of chemokines, chemokine receptors and interleukin-6 in patients with panic disorder, personality disorders and their co-morbidity. <i>Pharmacological Reports</i> , 2016, 68, 756-763.	3.3	7
16	Evaluation of ADMA, carbonyl groups, CAT and NKA in depressed patients with and without posttraumatic stress disorder. <i>Pharmacological Reports</i> , 2017, 69, 730-737.	3.3	6
17	Depressive disorders co-existing with Addison–Biermer anemia – case report. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1145.	2.2	5
18	A female patient with depression and conversion disorder following brain tumor surgery. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 1213-1214.	2.3	4

#	ARTICLE	IF	CITATIONS
19	Bipolar disorder: Mixed episodes concomitant with gambling addiction. Australian and New Zealand Journal of Psychiatry, 2014, 48, 586-587.	2.3	3
20	Electroconvulsive therapy in a patient with drug-resistant depression and thyroid hormone imbalance. Australian and New Zealand Journal of Psychiatry, 2014, 48, 96-97.	2.3	3
21	Alexithymia and Emotional Deficits Related to Posttraumatic Stress Disorder: An Investigation of Content and Process Disturbances. Case Reports in Psychiatry, 2022, 2022, 1-5.	0.5	2
22	Asymmetric dimethylarginine (ADMA) as a predictor of depression. European Neuropsychopharmacology, 2016, 26, S468-S469.	0.7	0